[{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Sino Biopharmaceutical","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.94999999999999996,"dosageForm":"Injection","sponsorNew":"Sino Biopharmaceutical \/ LaNova Medicines","highestDevelopmentStatusID":"10","companyTruncated":"Sino Biopharmaceutical \/ LaNova Medicines"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Series C Financing","leadProduct":"Apatinib","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Sino Biopharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Inventiva Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Lanifibranor","moa":"Peroxisome proliferator-activated receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sino Biopharmaceutical","amount2":0.31,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.31,"dosageForm":"Tablet","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Inventiva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"Peroxisome proliferator-activated receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sino Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Akeso","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Penpulimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sino Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Treadwell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"CFI-400945","moa":"||Serine\/threonine-protein kinase PLK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sino Biopharmaceutical","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Sinovac Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Funding","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sino Biopharmaceutical","amount2":0.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.5,"dosageForm":"Injection","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Sino Biopharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Upon completion of the acquisition, LaNova will become a wholly owned subsidiary of Sino. Its lead product, LM-302, is being evaluated for the treatment of CLDN18.2-positive gastric cancer.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          July 15, 2025

                          Lead Product(s) : LM-302

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : LaNova Medicines

                          Deal Size : $951.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The financing is intended to support the clinical development of LM-302, an anti-CLDN 18.2 ADC, which is currently in late-stage clinical trials in China for the treatment of gastric cancers.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          October 18, 2024

                          Lead Product(s) : LM-302,Apatinib,Irinotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : LaNova Medicines

                          Deal Size : $42.0 million

                          Deal Type : Series C Financing

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : IVA337 (Lanifibranor), is an orally-available small molecule which induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three PPAR isoforms, regulating gene expression.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 25, 2023

                          Lead Product(s) : Lanifibranor

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase III

                          Recipient : Inventiva Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lanifibranor (IVA337), is an orally-available small molecule with breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) following a positive Phase IIb trial in patients with non-alcoholic steatohepatitis (NASH).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : $12.0 million

                          September 21, 2022

                          Lead Product(s) : Lanifibranor

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase III

                          Recipient : Inventiva Pharma

                          Deal Size : $307.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform, as well as general corporate purposes.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          November 18, 2021

                          Lead Product(s) : CFI-400945,Azacitidine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Treadwell Therapeutics

                          Deal Size : $91.0 million

                          Deal Type : Series B Financing

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Penpulimab is currently the only new PD-1 monoclonal antibody that applies IgG1 subtype and is modified by Fc segment, which has a lower antigen binding dissociation rate and a unique binding epitope as demonstrated by analysis on crystal structure.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          August 05, 2021

                          Lead Product(s) : Penpulimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Akeso

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The investment deal comes as Sinovac expands supply deals and trials of its experimental COVID-19 vaccine CoronaVac with more countries following positive results from early to mid-stage clinical trials.

                          Product Name : CoronaVac

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          December 07, 2020

                          Lead Product(s) : Inactivated Vero Cell

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Sinovac Biotech

                          Deal Size : $500.0 million

                          Deal Type : Funding

                          blank